Lung Cancer

Treatment Paradigm for Lung Cancer Shifting Toward Targeted Therapies, Immunotherapy

Wayne Kuznar

May 2014, Vol 5, No 4 - Lung Cancer

Hollywood, FL—Driver mutations, most frequently KRAS and EGFR, account for approximately 50% of non–small-cell lung cancer (NSCLC), and this recognition is shifting the NSCLC treatment paradigm toward targeted therapy when possible, said Leora Horn, MD, MSc, Assistant Professor of Medicine, Division of Hematology/ Oncology, Vanderbilt University, Nashville, TN, at the 2014 National Comprehensive Cancer Network Conference. [ Read More ]

Task Force Recommends Annual Screening for Lung Cancer in High-Risk Populations

Neil Canavan

February 2014, Vol 5, No 1 - Lung Cancer

The US Preventive Services Task Force (USPSTF) is recommending that individuals aged >55 years who have a history of heavy smoking be screened annually for lung cancer.

If adopted, this initiative will bring an estimated 14% reduction in lung cancer–related mortality as a result of early disease detection, according to the USPSTF position paper, which was recently published online (Moyer VA. Ann Intern Med. 2014 January 14. Epub ahead of print).

[ Read More ]